LeoSat Responds to National Science Foundation RFI for Antarctic Broadband Network
LeoSat Enterprises, an emerging company with plans to launch a constellation of up to 108 low-earth-orbit communications satellites that will provide the fastest, most secure and widest coverage data network in the world, has announced it has been invited by the National Science Foundation (NSF) to respond to their Request for Information (RFI) for broadband data communications requirements in the South Pole and throughout the Antarctic continent.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160614005541/en/
LeoSat Enterprises Satellite Constellation (Phto: Business Wire)
Data communication to and from the Polar regions is challenging and expensive. Building cable networks is hardly feasible from an economic perspective and satellite connections using the traditional GEO arc come at low speed, high costs and operational challenges. For bulk data there is no viable solution and all too often the data needs to be physically carried out to its destination. For research communities this causes serious delays and additional costs.
NSF is an independent federal agency that supports fundamental research and education across all fields of science and engineering. Under a Presidential mandate, NSF manages the U.S. Antarctic Program, through which it coordinates all U.S. research on the Southernmost Continent and the surrounding ocean, funds scientists at institutions nationwide to carry out fieldwork and provides the logistical support for that fieldwork.
While the NSF’s two RFIs have been out for some time and suspense dates have passed, NSF has continued its market research information gathering for formulating its plans. Having noted the public announcements by LeoSat, NSF has reached out to LeoSat with a request to respond to the the RFIs to allow LeoSat’s information to be included in NSF’s planning. With the LeoSat network, the satellites will be placed in polar orbits, making the Antarctic region one of the best served regions in the world with fiber-like speeds and low latency.
LeoSat’s CEO, Mark Rigolle, said: “We are excited to be singled out by such a prominent agency as the National Science Foundation. We take that as a strong endorsement of our plans to offer global, low-latency, high-throughput satellite capacity, using a Low Earth Orbit constellation. As indeed our satellites are flown in polar planes, there is good fit with NSF’s requirements. In addition, the large data-transmission requirement, which, as per the two RFI’s is in the terabytes per day, can easily be delivered by the constellation that we plan to launch starting 2019. As such, we hope to work with the NSF in an effort to solve their bandwidth requirements in this challenging part of the world”.
When fully operational, LeosSat will provide point-to-point data connections to and from anywhere on earth without the need for any terrestrial landings or transport. The data will be able to travel in its native form while encrypted and secured from end to end. LeoSat has completed a feasibility study with Thales Alenia Space for its constellation design and deployment and is currently working with them on the next phase of development.
About LeoSat Enterprises
LeoSat Enterprises was established in 2013 to leverage the latest developments in satellite communications technologies to develop and launch a new low-earth-orbit satellite constellation which will provide the first commercially available, business grade, extremely high-speed and secure data service worldwide.
With up to 108 low-earth-orbit communications satellites in the constellation LeoSat is the first company to have all of the High Throughput Satellites (HTS) in the constellation connected together in networked HTS satellites, connected to each other and to select established sectors on the planet.
Based in Washington DC, LeoSat is currently working with Thales Alenia Space for the low-earth-orbit constellation of between 78 and 108 Ka-band communications satellites. Once operational, the constellation will provide high-speed, low-latency and highly secure communications and bandwidth for business operations in the telecom backhaul, Oil & Gas exploration, Maritime and international business markets. Launch of the constellation is expected in 2018 or 2019. www.leosat.com
LeoSat Marketing Communications
Tel: +31 6 14 22 97 62
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28 | Pressemelding
Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (http://www.elektroniknet.de), a leading German electronics publication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005646/en/ Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05 | Pressemelding
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52 | Pressemelding
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50 | Pressemelding
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00 | Pressemelding
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on